Drug Interactions Corner

Back to articles

Newer hepatitis C regimens interact with warfarin

KEY POINT

Newer hepatitis C virus (HCV) drug regimens are associated with decreased warfarin responses, with the combination of ombitasvir–paritaprevir–ritonavir and dasabuvir ([OBV–PTV–r/DSV] Viekira—Abbvie) causing the greatest reduction followed by sofosbuvir-containing (Sovaldi—Gilead) regimens.

SOURCES

DeCarolis DD, et al. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother. 2016;[Epub ahead of print].